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Abstract
Tumor viruses are linked to approximately 20% of human malignancies worldwide. This review
focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset
of viral malignancies; those associated with AIDS. The viruses include Kaposi's sarcoma
herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's
sarcoma, certain B-cell lymphomas and cervical cancer, respectively. We discuss the molecular
mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-
cancer therapy from the perspective of this system.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Introduction
Viruses are etiologically linked to approximately 20% of
all human malignancies worldwide and much of what we
know today about the molecular mechanisms of onco-
genesis has come from the study of tumor viruses. The
means by which viruses subvert the ubiquitin proteasome
system (UPS) is a relatively new area of inquiry. The study
of the interactions between viruses and this system not
only furthers knowledge of how viruses work, but also
often offers shortcuts to understanding cellular processes
in general. Though the infectious nature of viruses distin-
guishes them from other oncogenic factors, it is the adap-
tation of tumor viruses, mainly DNA viruses, over
millennia of co-evolution with their hosts to persistence
within these hosts that make the viruses an ideal focus for
study of cellular mechanisms reviewed briefly here. This
perspective is valid because the immense array of normal
intracellular regulatory mechanisms is for the most part
intact in latently infected cells, even when they become
neoplastic. This symbiosis between virus and cell is mir-
rored by the fact that in most infected individuals tumors
do not develop, and in most instances many years pass
between initial infection and appearance of a tumor. The
host immune system generally keeps viral infection under
control; however, conditions such as acquired immune
deficiency syndrome (AIDS) elevate the risk of virus-asso-
ciated malignancies dramatically [1-4].
Although human immunodeficiency virus (HIV), the
cause of AIDS, itself does not have oncogenic properties,
the profound immunodeficiency it causes creates a favora-
ble environment for the development of cancer. All HIV-
infected patients are at increased risk of developing several
types of cancer, particularly in the later stages of AIDS.
Despite highly active anti-retroviral therapy (HAART)
being widely employed in developed countries, malig-
nancy in this population is still a leading cause of morbid-
ity and mortality [2,5,6].
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AIDS are Kaposi's sarcoma, immunoblastic B-cell lym-
phomas and an increased incidence of cervical and anal
carcinoma [7,8]. Three human oncogenic viruses are
involved causally: Kaposi's sarcoma herpesvirus (KSHV),
Epstein-Barr virus (EBV) and human papilloma virus
(HPV) [9,10].
AIDS-related malignancies represent only a small portion
of all virus-associated human cancers. The consistency of
association between a given virus and a specific malig-
nancy ranges from essentially 100% to as low as 15%
depending on the virus, the cancer and other factors [11].
Since the UPS regulates diverse cellular functions, includ-
ing transcription, stress responses, cell cycle, cellular dif-
ferentiation, angiogenesis, antigen processing and DNA
repair [12], it is inevitably involved in oncogenesis
induced by all the human tumor viruses [13,14].
Here we discuss several examples of how three tumor
viruses manipulate the UPS in AIDS-associated viral
malignancies, as well as provide perspectives on UPS-
directed agents that might offer pathways to therapeutic
intervention in these diseases.
Kaposi's sarcoma and KSHV
The search for a transmissible infectious agent as the cause
of Kaposi's sarcoma led to the discovery in 1994 of KSHV,
so far the newest member of the group of identified
human oncogenic viruses [15-17]. Even though the inci-
dence of Kaposi's sarcoma has fallen since the introduc-
tion of HAART, it is still the most common cancer
associated with AIDS [18-21].
The ability to evade immune responses is crucial for long-
term survival of viruses in the host. Oncogenic viruses
make use of diverse strategies in achieving survival; one is
the down-regulation of major histocompatibility complex
(MHC) class I antigen presentation through the UPS
[22,23].
KSHV encodes several viral products with oncogenic prop-
erties, among them two proteins, K3 and K5 (also known
as MIR1 and MIR2), that have ubiquitin ligase activity
[24,25]. K3 and K5 recruit E2 enzymes with their N-termi-
nal RING-CH domain [25]. Either direct or indirect inter-
actions between the transmembranes of K3 and K5 and
MHC class I molecules ultimately lead to the ubiquityla-
tion of lysine residues present in the MHC class I intracy-
toplasmic tail [25,26]. Ubiquitylated MHC class I
molecules are then endocytosed and degraded by the lys-
osome [25,27,28]. A recent report indicates that K3, but
not K5, can promote down-regulation of MHC class I
molecules lacking lysine residues in their intracytoplasmic
domains [29]. Another study argues that lysine 63-linked
ubiquitylation of MHC class I molecules is necessary for
their efficient K3 ubiquitin ligase-mediated endolyso-
somal degradation [30].
Besides K3 and K5, another KSHV product, the immedi-
ate-early transcriptional transactivator RTA, is reported to
encode E3 ubiquitin ligase activity [31]. RTA-dependent
ubiquitylation of interferon regulatory factor 7 (IRF7), a
key inducer of interferon-stimulated genes (ISGs), could
target it for ubiquitin-dependent proteasomal degrada-
tion [31], thus dampening innate immune responses to
the infection.
B-cell lymphomas and EBV
Several decades of intensive studies on EBV, the first
human oncogenic virus discovered, have revealed its asso-
ciation with a variety of malignant diseases [11,32-37],
including B-cell lymphomas associated with acquired and
innate immunosuppressive conditions [38-42].
The EBV product EBNA1 represents an interesting exam-
ple of how a virus evades immune system responses.
EBNA1 is a nuclear protein that binds to EBV episomes
and is required for maintenance of latency by the virus
[34]. This viral protein contains repeats of Gly-Ala resi-
dues that prevent its proteasomal degradation and, addi-
tionally, sequester cleaved viral products in a cytoplasmic
compartment, rendering them inaccessible for presenta-
tion by MHC class I molecules [43]. Although EBNA1 is
not the only viral protein expressed during EBV latency, its
resistance to UPS-dependent degradation creates a perfect
camouflage to prevent recognition by the immune system
[43-45].
Like other tumor viruses, EBV demonstrates its oncogenic
potential by redirecting cell signaling pathways. Recent
studies reveal ways in which EBV can manipulate different
components of the UPS. For example, in B-cells its major
oncogenic product, latent membrane protein 1 (LMP1),
inhibits Siah-1 ubiquitin ligase to rescue the oncogenic
factor β-catenin from proteasomal degradation [46,47]. In
contrast, in epithelial cells LMP1 activates the same ubiq-
uitin ligase, the targets of which in this case are prolyl
hydroxylases (PHDs) [48]. These enzymes mark hypoxia-
inducible factor-1α (HIF1α for degradation by the UPS.
The stability of PHD 1 and PHD 3 is regulated by both
Siah-1 and Siah-2 ubiquitin ligases [49]. The result of
LMP1-dependent Siah up-regulation in epithelial cells is
that HIFα levels are increased and become active HIFα-
responsive genes [48,50]. These are recent observations
and physiological reasons for the distinct functional roles
of Siah ubiquitin ligases in the different cell types are
unknown.Page 2 of 7
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as a surrogate B-cell receptor by providing constitutive sig-
naling required for B-cell development and survival [51].
LMP2A signaling appears to be regulated in B-cells by
association with members of the HECT domain-contain-
ing Nedd4 family of ubiquitin ligases [52,53] and likely
utilizes ubiquitin-mediated degradation through the pro-
teasome complex to regulate the strength of its own sig-
nal. Such processes could allow LMP2A to modulate B-cell
pathways such as differentiation, activation or survival
[51].
A further EBV latent antigen, EBNA 3C, targets the tumor
suppressor pRb for proteasome-dependent degradation
through the well known SCFSkp2 ubiquitin ligase in differ-
ent systems including B-cells [54]. Besides directing ubiq-
uitylation that leads to proteasomal degradation, EBV can
also affect the regulatory lysine 63 ubiquitylation of IRF7
(the master regulator of type I IFN responses), which leads
to its activation instead of degradation [55].
Cervical carcinoma and HPV
While Kaposi's sarcoma and B-cell lymphoma are the
main viral malignancies associated with AIDS, and their
connection with HIV infection are hallmarks of the condi-
tion, the association between HIV/AIDS and cervical and
anal cancer is less obvious [56,57]. However, in 1993 a
revised classification system for HIV infection listed inva-
sive cervical cancer as one of the AIDS-defining malignan-
cies [58], and there is growing evidence that HIV infection
is associated with increased prevalence and severity of
HPV-containing malignant cervical lesions [9,59,60].
More than 95% of all cervical carcinomas contain at least
one copy of one of the HPV genotypes 16 & 18 as well as
other types that pose a high risk for the malignancy [61].
The HPV E6 and E7 genes are the only viral genes that are
retained and expressed in tumor tissue, and their role in
HPV-induced carcinogenesis is well established [61-63].
Both proteins cause down-regulation of crucial tumor
suppressors; E6 inhibits p53 [64-68] and E7 inactivates
the retinoblastoma family proteins (pRb) [69-72]. Both
E6 and E7 utilize the UPS to target these proteins for deg-
radation and thus inactivation [73]. These interactions are
recognized as classic oncogenic mechanisms; they operate
in place of mutation of p53 and pRb.
HPV E6 recruits E6-associated protein (E6-AP), now rec-
ognized to be an E3 ligase; this E6-E6-AP complex then
binds to p53, resulting in E6-AP-mediated ubiquitylation
and proteasomal degradation of p53 [67,74,75]. From the
perspective of cancer cell biology, this interaction is of
interest because the virus product alters endogenous sub-
strate specificity; normally, p53 is a target for Mdm2 ubiq-
uitin ligase-mediated ubiquitylation and degradation
[76,77].
The mechanism of E7-induced proteasomal degradation
of pRb is still unclear [73,78]. One possibility is that E7
recruits a cellular ubiquitin ligase that targets pRb for
ubiquitylation and subsequent degradation. This model is
supported by the finding that co-expression of pRb with
the Rb-binding-deficient E7 mutant causes a consistent
increase in pRb-induced contact-inhibited cell growth in
culture [79]. Another possibility is that E7 could function
as an adaptor between pRb and the proteasome, thereby
targeting pRb directly to the proteasome without prior
ubiquitylation, since it has been reported that E7 interacts
with the ATPase subunit of the 19S regulatory complex of
the 26S proteasome [80].
Disease models, knockouts and assays
Animal models that mimic human cancers caused by
viruses are obviously important for understanding the
tumor biology of AIDS-associated malignancies, as well as
for evaluating the effect of potential anti-tumor and anti-
viral drugs. Although there is currently still no animal
model that accurately represents KSHV, EBV or HPV
pathogenesis, mouse models have been established that
attempt to address specific factors known to contribute to
the development of the diseases. For example, murine
gammaherpesvirus 68 (γHV-68) is used as a rodent model
to help understand the pathogenesis of EBV and KSHV.
Several reviews of γHV-68 have documented advances
made toward understanding the pathogenesis of AIDS-
associated malignancies in the context of these two
human viruses [81-83].
Another approach is the transplantation of human tumor
tissue to mice with severe combined immunodeficiency
disease (SCID), which provides valuable models for viral
carcinogenesis and also demonstrates the strict species
barrier for infection by human viruses [84-87].
As for the roles of the UPS in virus-related cancers, cul-
tured cell lines are still the primary model used at present
to study the relations between viral oncogenes and the
components of the UPS.
Crucial proof of the transforming potential of KSHV came
from de novo infection of cultured bone marrow (microv-
ascular) endothelial cells and human umbilical vein
endothelial cells (HUVECs). KSHV infection conferred
long-term survival of both cell types and anchorage-inde-
pendent growth of HUVECs [88]. Continuous KSHV
infection and also conditional, productive viral replica-
tion in cells cultured from primary effusion lymphoma
(PEL) (a rare B-cell non-Hodgkin's lymphoma) [89] pro-
vide additional models.Page 3 of 7
(page number not for citation purposes)
BMC Biochemistry 2007, 8(Suppl 1):S8 http://www.biomedcentral.com/1471-2091/8/S1/S8The ability of EBV to immortalize normal human B-lym-
phocytes in vitro and to transform them into lymphoblas-
toid cell lines (LCLs) generates a cell-culture model of
AIDS-associated EBV lymphomas [90]. Virus-containing
B-lymphoblastoid cell lines that have been derived from
primary tumors are also suitable as in vitro model systems
[91].
Numerous cell lines infected with HPV serve as model cell
culture systems to study different aspects of tumorigene-
sis, but perhaps the most relevant system for evaluating
the transforming potential of the HPV oncoproteins is
immortalization of primary human keratinocytes, which
are the natural host cells of this virus in vivo[92]. HPV-
immortalized cells are not tumorigenic in nude mice,
although they display altered growth and differentiation.
Due to the oncogenic properties of HPV E6 and E7, these
proteins have been the focus of most studies on cervical
carcinogenesis [64,93-95]. Although the majority of the
studies have been performed using cell culture models,
several in vivo mouse model systems have been developed
for the study of HPV-dependent carcinogenesis [96].
Disease targets and ligands
Both HPV E6 and E7 dysregulate the UPS so that there is
down-regulation of the tumor suppressors p53 and pRb.
Since both E6 and E7 are immunogenic, these viral prod-
ucts present potential targets for therapeutic vaccines [97-
101].
As the UPS is closely involved in the regulation of numer-
ous signaling pathways in tumor cells, it has in the last
several years become an attractive target for anti-cancer
therapy. The use of proteasome inhibitors to block the
final stage in the UPS, proteolysis in the proteasome,
presents the opportunity to manipulate intracellular proc-
esses in cancer cells for tangible benefit [102-106]. Yet, the
functional activity of the UPS is crucial for normal cell
function; blockade of protein degradation by proteasome
inhibitors causes accumulation of misfolded or damaged
proteins, which in turn leads to cell death [107,108]. At
the same time, there is much evidence that some proteas-
ome inhibitors are more cytotoxic to proliferating malig-
nant cells than to normal quiescent cells [109].
The first of this new proteasome-inhibiting class of drugs
to be on the market, bortezomib (Velcade, formerly
known as PS-341), shows promising results in clinical tri-
als with different types of cancer specifically by inhibiting
the oncogenic NF-κB signaling pathway [110,111]. Since
UPS-dependent degradation of IκB leads to NF-κB activa-
tion (as observed in most known malignancies including
those that are AIDS-related [112]), bortezomib could be a
candidate for the treatment of the virus-related cancers. In
in vitro studies, bortezomib has demonstrated activity
against a variety of malignancies by inducing apoptosis in
cancer cells and increasing sensitivity of tumor cells to
radiation or chemotherapy [113]. Since bortezomib is
proving to be highly efficient for treatment of multiple
myeloma and also shows promise for lymphoid cancers
[113,114], it could be useful in the treatment of EBV-
induced B-lymphomas, which are the second most com-
mon AIDS-related malignancy.
Since latent infection with these three DNA viruses is the
basis for tumorigenesis, induction of the viral lytic cycle,
leading to death of virus-infected malignant cells, is a
potential antiviral strategy [115,116]. Recent study shows
that bortezomib induces KSHV lytic gene expression in
vitro in two latently KSHV-infected lymphoma cell lines
[117]. This result suggests that the UPS regulates viral reac-
tivation and that proteasome inhibitors could have simi-
lar effects on other latently infected virus-associated
malignant cells.
Also, targeting of other steps of the UPS, such as specific
ubiquitin ligases or deubiquitylating enzymes, could pro-
duce more selective effects since ubiquitylating and deu-
biquitylating complexes specifically bind to potential
substrates. KSHV ubiquitin ligases K3 and K5 could be
good examples of such targets.
Next frontiers
The effect of bortezomib and other proteasome inhibitors
in virus-associated malignancies needs to be defined fur-
ther. Viral products themselves are closely involved in
UPS-dependent regulation and therefore the effects of
proteasome inhibitors can be unexpected. For instance, it
has been shown on one hand that proteasome inhibitors
inhibit HIV budding [118] and on the other hand that
inhibition of proteasome function can enhance HIV-1
infection [119].
Generally, present knowledge of how UPS modulators
affect AIDS/HIV-associated or other virus-related malig-
nancies is very limited and calls for further investigation.
Recent information on the relations between tumor
viruses and the host cell system is summarized in Table 1.
Despite the limitations of in vivo model systems for virus-
related human malignancies, some (for example, human
peripheral blood lymphocytes (hu-PBL) engrafted in
SCID mice) could facilitate screening and preliminary
testing of proteasome inhibitors.
Finally, there is no doubt that in the broader panorama of
other cancers associated with viruses, such as human T-
cell lymphotropic virus-1 (HLTV-1: leukemia), hepatitis B
and C viruses (HBV and HCV: hepatocellular carcinoma),Page 4 of 7
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Burkitt's and Hodgkin's lymphomas) and HPV (cervical
cancer) in non-immunocompromised patients, many
aspects of the UPS are at work and will offer targets for
therapy.
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